THE DEAL: Thermo Fisher Scientific Inc. said Monday that it plans to pay about $13.6 billion, or $76 per share, for Life Technologies Corp.
THE STRATEGY. The deal positions Thermo Fisher to benefit from the expected growth of personalized medicine, which uses genetic analysis to tailor treatments to patients. Analysts also expect the companies to reap savings from the combination and gain leverage in negotiating with suppliers.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.